Phaseline

Companies › Chia Tai Tianqing Pharmaceutical Group

Chia Tai Tianqing Pharmaceutical Group: clinical trials, targets and expected readouts

34 active drug programs in 164 registered trials: 89 Phase 2, 36 Phase 1, 22 Phase 3, 17 Phase 4; Oncology, Infectious disease, Other, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Catequentinib
Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor
KDR, FLT4, KIT, PDGFRBPhase 4Medullary Thyroid Cancer; Advanced Hepatocellular Carcinoma (HCC); Metastatic Colorectal Cancer; Hepatocellular Carcinoma …Dec 2026
Adalimumab
TNF-alpha inhibitor
TNFPhase 4Adult Non-infectious Uveitis; Crohn's Disease; Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's Disease; Takayasu Arteritis …Feb 2028
Penpulimab
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Advanced Hepatocellular Carcinoma (HCC); Hepatocellular Carcinoma; Advanced Pancreatic Cancer; Nasopharyngeal Neoplasms …Dec 2026
TQ05105 Tablets (Rovadicitinib Tablets)
Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), and Rho-associated coiled-coil containing pr
JAK1, JAK2, ROCK2Phase 3Graft-versus-host Disease; Chronic Graft Versus Host Disease; MyelofibrosisDec 2026
TQB3454 tablets
Selective IDH1 mutant enzyme inhibitor
IDH1Phase 3Biliary CarcinomaDec 2026
TQB3616 capsule
CDK2/4/6 inhibitor
CDK2, CDK4, CDK6Phase 3HR-positive, HER2-negative Breast Neoplasms; Breast Cancer; Metastatic Breast CancerDec 2026
AL2846 Capsule
Multi-target tyrosine kinase inhibitor targeting c-MET, c-KIT, VEGFR1, and RET
MET, KIT, FLT4, RETPhase 3Thyroid CancerJan 2027
TQB2102 for Injection
HER2 antibody-drug conjugate
ERBB2Phase 3Breast CancerJan 2027
TQC3721 Suspension for Inhalation
Phosphodiesterase 3/4 (PDE3/4) inhibitor
PDE3, PDE4Phase 3Chronic Obstructive Pulmonary DiseaseFeb 2027
TQB3473
Spleen tyrosine kinase (Syk) inhibitor
SYKPhase 3Primary Immune ThrombocytopeniaMar 2027
Angiotensin Ii
Type-1 angiotensin II receptor agonist
AGTR1Phase 3Vasodilatory Shock; Vasodilatory Hypotension During or After Cardiac Surgery; Cirrhosis, Liver; Septic Shock …Jun 2027
D-1553 Tablet
KRAS G12C inhibitor
KRASPhase 3Non Small Cell Lung CancerDec 2027
TQ-B3234 capsules
Selective MEK1/2 inhibitor
MAP2K1, MAP2K2Phase 3Plexiform NeurofibromaDec 2027
TQ-A3334
Viral replication inhibitor (HBV)
–Phase 2Chronic Hepatitis BDec 2026
TQB2450 injection
humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1)
PDCD1LG1Phase 2Non Small Cell Lung CancerDec 2026
TQD3524
Polymyxin E2 methanesulfonate; hydrolyzed to polymyxin E2 and derivatives with bactericida
–Phase 2Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial PneumoniaJul 2027
Benmelstobart injection
PD-L1 inhibitor
PDCD1LG2Phase 2Alveolar Soft Part SarcomaNov 2027
TQB3702 tablets
Tyrosine kinase inhibitor
–Phase 2B-cell LymphomaDec 2027
TQB2825 injection
CD20/CD3 bispecific antibody
CD20, CD3Phase 1Diffuse Large B Cell LymphomaDec 2026
TQB2930 for injection
HER2 bispecific antibody
ERBB2Phase 1Metastatic Breast CancerDec 2026
TQB3122 Capsules
PARP1 inhibitor
PARP1Phase 1Advanced CancerDec 2026
TQB3455 tablet
IDH2 mutant enzyme inhibitor
IDH2Phase 1Acute Myeloid Leukemia (AML)Dec 2026
TQB3617 Capsules
Bromodomain and Extra-Terminal (BET) inhibitor
BRD2, BRD3, BRD4, BRDTPhase 1MyelofibrosisDec 2026
TQF3250 capsules
glucagon-like peptide-1 receptor agonist
GLP1RPhase 1Hyperglycemia; Overweight/Obesity; Type 2 Diabetes Mellitus Combined With Overweight or ObesityDec 2026
TQB6411 for Injection
EGFR/c-Met dual-targeting antibody-drug conjugate
EGFR, METPhase 1Esophageal Cancer; Advanced Lung CancerFeb 2027
TQB3107 Tablets
selective target inhibitor that binds to target to induce apoptosis
–Phase 1Advanced CancersJun 2027
LM-108 injection
monoclonal antibody that selectively clears regulatory T cells (Tregs) infiltrating tumor
–Phase 1Advanced Pancreatic Cancer; TNBC - Triple-Negative Breast CancerDec 2027
TQB3019 capsule
targeted protein degrader
–Phase 1Advanced Malignant CancerDec 2027
TQB3142 for injection
BCL-XL inhibitor
BCL2L1Phase 1Advanced Malignant TumorsDec 2027
TQB3205 capsule
targeted protein degrader
–Phase 1Advanced Malignant CancerDec 2027
TQB3126
targeted protein degrader
–Phase 1Breast CancerAug 2029
TQA3605 tablets
Viral replication inhibitor
–Phase 1Chronic Hepatitis b–
TQB3002
EGFR tyrosine kinase inhibitor
EGFRPhase 1Advanced Cancer–
TQB3909
Protein inhibitor
–Phase 1Myeloid Malignancy–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04300686AdalimumabPhase 4Takayasu ArteritisImmunologyMay 2022
NCT06482086CatequentinibPhase 2Locally Advanced Thyroid Gland CarcinomaOncologyDec 2024
NCT05365178TQB3616 capsulePhase 3HR-positive, HER2-negative Breast NeoplasmsOncologyJul 2025
NCT05807880CatequentinibPhase 2Nasopharyngeal NeoplasmsOncologyJul 2025
NCT05807880PenpulimabPhase 2Nasopharyngeal NeoplasmsOncologyJul 2025
NCT07011186TQB3909Phase 1Myeloid MalignancyOncologyOct 2025
NCT06662760TQB3002Phase 1Advanced CancerOncologyNov 2025
NCT04743518AdalimumabPhase 4Ulcerative ColitisImmunologyDec 2025
NCT06150014TQA3605 tabletsPhase 1Chronic Hepatitis bInfectious diseaseDec 2025
NCT05685550CatequentinibPhase 2Progression Free Survival(PFS)OtherDec 2025
NCT06487585Angiotensin IiPhase 4Vasodilatory Hypotension During or After Cardiac SurgeryCardiovascularJan 2026
NCT03938701AdalimumabPhase 2IBDImmunologyMar 2026
NCT06886347CatequentinibPhase 1Metastatic Nasopharyngeal CarcinomaOncologyApr 2026
NCT06939452CatequentinibPhase 2Advanced Gastric or Gastroesophageal Junction (G/GEJ) AdenocarcinomaOncologyJun 2026
NCT05828953CatequentinibPhase 2Interstitial Lung DiseasesRespiratorySep 2026
NCT01426529Angiotensin IiPhase 1HypertensionCardiovascularOct 2026
NCT05926700CatequentinibPhase 2Soft Tissue SarcomaOncologyDec 2026
NCT06122831TQ05105 Tablets (Rovadicitinib Tablets)Phase 1MyelofibrosisOncologyDec 2026
NCT07480824TQ05105 Tablets (Rovadicitinib Tablets)Phase 1MyelofibrosisOncologyDec 2026
NCT07708272TQ05105 Tablets (Rovadicitinib Tablets)Phase 1MyelofibrosisOncologyDec 2026
NCT07608666TQ05105 Tablets (Rovadicitinib Tablets)Phase 1MyelofibrosisOncologyDec 2026
NCT04344158CatequentinibPhase 3Advanced Hepatocellular Carcinoma (HCC)OncologyDec 2026
NCT04854668CatequentinibPhase 3Metastatic Colorectal CancerOncologyDec 2026
NCT05862337CatequentinibPhase 3Hepatocellular CarcinomaOncologyDec 2026
NCT05913089CatequentinibPhase 2Non Small Cell Lung CancerOncologyDec 2026
NCT06838910CatequentinibPhase 2Thymic CarcinomaOncologyDec 2026
NCT05780567TQB3616 capsulePhase 3Breast CancerOncologyDec 2026
NCT06702618TQB3616 capsulePhase 2Breast CancerOncologyDec 2026
NCT06202261TQB3616 capsulePhase 1Metastatic Breast CancerOncologyDec 2026
NCT07269145TQB3122 CapsulesPhase 1Advanced CancerOncologyDec 2026
NCT06122831TQB3617 CapsulesPhase 1MyelofibrosisOncologyDec 2026
NCT04344158PenpulimabPhase 3Advanced Hepatocellular Carcinoma (HCC)OncologyDec 2026
NCT05862337PenpulimabPhase 3Hepatocellular CarcinomaOncologyDec 2026
NCT05576480PenpulimabPhase 2Rectal CancerOncologyDec 2026
NCT07327281TQF3250 capsulesPhase 1HyperglycemiaOtherDec 2026
NCT06202261TQB2930 for injectionPhase 1Metastatic Breast CancerOncologyDec 2026
NCT06829771TQB2825 injectionPhase 1Diffuse Large B Cell LymphomaOncologyDec 2026
NCT06706310TQ-A3334Phase 2Chronic Hepatitis BInfectious diseaseDec 2026
NCT05913089TQB2450 injectionPhase 2Non Small Cell Lung CancerOncologyDec 2026
NCT05987358TQB3454 tabletsPhase 3Biliary CarcinomaOncologyDec 2026
NCT06550713TQB3455 tabletPhase 1Acute Myeloid Leukemia (AML)OncologyDec 2026
NCT04592744Angiotensin IiPhase 4Cirrhosis, LiverGastroenterologyDec 2026
NCT05260671PenpulimabPhase 2Head and Neck NeoplasmsOncologyDec 2026
NCT05400070CatequentinibPhase 2SintilimabOncologyDec 2026
NCT05220267CatequentinibPhase 2Non Clear Cell Renal CarcinomaOncologyDec 2026
NCT06211790CatequentinibPhase 2Kidney CancerOncologyDec 2026
NCT06114225PenpulimabPhase 2OsteosarcomaOncologyDec 2026
NCT06081673PenpulimabPhase 2Head and Neck Squamous Cell CarcinomaOncologyDec 2026
NCT04944043TQ05105 Tablets (Rovadicitinib Tablets)Phase 1Chronic Graft Versus Host DiseaseImmunologyDec 2026
NCT06195228CatequentinibPhase 4Advanced Thyroid Cancer Patients Who Received Target TherapyOncologyDec 2026
NCT07806292CatequentinibPhase 2Unresectable Hepatocellular CarcinomaOncologyDec 2026
NCT04136535CatequentinibPhase 2NSCLC Stage IVOncologyDec 2026
NCT07025174CatequentinibPhase 2Bile Duct CarcinomaOncologyDec 2026
NCT06739395CatequentinibPhase 2Solid TumorOncologyDec 2026
NCT06249750CatequentinibPhase 2Metastatic Castration-resistant Prostate Cancer (CRPC)OncologyDec 2026
NCT06354530CatequentinibPhase 2Neoadjuvant TherapyOncologyDec 2026
NCT06379087CatequentinibPhase 2Non-Small Cell Lung CancerOncologyDec 2026
NCT06331169CatequentinibPhase 1Breast CancerOncologyDec 2026
NCT06693726Angiotensin IiPhase 4Septic ShockOtherDec 2026
NCT05535738AdalimumabPhase 2Skin InflammationImmunologyJan 2027

The 60 nearest readouts of 164 trials; the rest in the app.

Targets

FLT4 (2) KIT (2) ERBB2 (2) EGFR (2) MET (2) JAK1 (1) JAK2 (1) ROCK2 (1) TNF (1) KDR (1) PDGFRB (1) SYK (1)

Companies with the same targets

AstraZeneca Beijing Biotech Shanghai Henlius Biotech Jiangsu HengRui Medicine Pfizer Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Betta Pharmaceuticals Roche Yuhan Johnson & Johnson (Janssen)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.